SYRE
Spyre Therapeutics Inc.
NASDAQ: SYRE · HEALTHCARE · BIOTECHNOLOGY
$71.89
+4.75% today
Updated 2026-04-29
Market cap
$6.20B
P/E ratio
—
P/S ratio
650.22x
EPS (TTM)
$-1.98
Dividend yield
—
52W range
$12 – $75
Volume
1.1M
Spyre Therapeutics Inc. (SYRE) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.60M | $2.93M | $38.65M | $67.06M | $56.08M | $77.74M | $83.18M | $161.62M | $109.93M | $71.14M | $341.86M | $608.48M |
| Cash & equivalents | — | — | — | — | — | — | — | — | — | — | — | — |
| Current assets | $4.60M | $2.73M | $38.29M | $66.42M | $54.99M | $76.67M | $74.50M | $149.79M | $98.89M | $62.26M | $341.53M | $608.47M |
| Total liabilities | $1.41M | $1.06M | $2.55M | $4.10M | $5.74M | $10.31M | $23.10M | $21.79M | $25.98M | $20.84M | $157.84M | $90.68M |
| Current liabilities | $1.41M | $1.06M | $2.52M | $3.96M | $5.63M | $10.24M | $18.36M | $16.44M | $20.14M | $14.66M | $31.98M | $54.06M |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | — |
| Shareholder equity | — | — | — | — | — | — | — | — | — | — | — | — |
| Retained earnings | $-1.94M | $-12.28M | $-23.58M | $-45.28M | $-72.51M | $-116.86M | $-195.12M | $-276.01M | $-341.81M | $-425.62M | $-764.41M | $-972.43M |
| Accounts receivable | — | — | $1.70M | $1.22M | $3.08M | $300000.00 | — | — | $815000.00 | $375000.00 | — | — |
| Inventory | — | — | — | — | — | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — |